Corcept Therapeutics to Announce Fourth Quarter and Full Year Revenue and Corporate Update and Host Conference Call

Corcept Therapeutics to Announce Fourth Quarter and Full Year Revenue and 
Corporate Update and Host Conference Call 
MENLO PARK, CA -- (Marketwired) -- 01/27/14 --  Corcept Therapeutics
Incorporated (NASDAQ: CORT) today announced it will report fourth
quarter and full year 2013 revenue on January 30, 2014. The Company
will also host a conference call that day at 5:00 p.m. Eastern Time
(2:00 p.m. Pacific Time).  
Conference Call Information 
To participate, dial 1-888-771-4371 from the United States or
1-847-585-4405 internationally approximately 10 minutes before the
start of the call. The passcode is 36540064.  
A replay will be available through February 13, 2014 at
1-888-843-7419 from the United States and +1-630-652-3042
internationally. The passcode is 3654 0064.  
About Corcept Therapeutics Incorporated 
Corcept is a pharmaceutical company engaged in the discovery,
development and commercialization of drugs for the treatment of
severe metabolic, psychiatric and oncologic disorders. Korlym, a
first generation GR antagonist, is the company's first FDA-approved
medication for use in the treatment of patients with Cushing's
syndrome. Corcept has a phase 3 trial underway for mifepristone for
treatment of the psychotic features of psychotic depression, as well
as a portfolio of selective GR antagonists that block the effects of
cortisol without blocking the effects of progesterone. It owns
extensive intellectual property covering the use of GR antagonists,
including mifepristone, in the treatment of a wide variety of
disorders. It also holds composition of matter patents for its
selective GR antagonists. For more information about Corcept please
visit: www.corcept.com 
CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
crobb@corcept.com
www.corcept.com 
 
 
Press spacebar to pause and continue. Press esc to stop.